New research on treating Gulf War Illness (GWI) is being presented this week at the Military Health Research Forum (MHRF), a scientific meeting hosted by the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP).
GWI is a condition that affects approximately 25 percent of service men and women who served in the 1990-1991 Gulf War. It is characterized by symptoms including fatigue, headache, joint pain, sleep disturbances, and memory problems, and is potentially a result of the veterans' exposure to toxic elements during their time on duty.
The study was funded by the Gulf War Illnesses Research Program (GWIRP) and managed by the CDMRP. The GWIRP strives to improve the health and lives of veterans who have GWI by supporting innovative research to improve its diagnosis, to better understand its pathobiology and to identify effective treatments for its array of symptoms.
"This program represents much needed movement to address the health concerns of those individuals who served the United States during the Gulf War," said Captain E. Melissa Kaime, M.D., director of the CDMRP. "In order to further assist our veterans, more extensive research of GWI and effective treatments for its various conditions is much needed."
A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Mifepristone in Gulf War Veterans with Chronic Multisymptom Illness (CMI)
Principal Investigator: Julia Golier, M.D., Bronx Veterans Medical Research Foundation, Inc.
A large percentage of Gulf War veterans – estimates range from 34 to 65 percent – continue to suffer from chronic multisymptom illness, also known as GWI. Symptoms can include fatigue, joint pain, headache, rash and cognitive problems, which may reflect altered regulation of the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is responsible for regulating many things in the body, from the immune system and energy usage, to controlling reactions to stress and trauma. Abnormal functioning of the HPA leads to negative effects on many systems in the body, including the immune system and the nervous system.
Studies have shown that veterans of the 1991 Gulf War have an enhanced neuroendocrine response to a specific type of hormone called glucocorticoids. The increased physical response is associated with chronic fatigue syndrome, fibromyalgia and post-traumatic stress disorder, all of which can occur with chronic multisymptom illness. This study aims to determine if mifepristone, a glucocorticoid receptor antagonist, could decrease the enhanced response and therefore improve the physical and mental health and cognitive functioning of Gulf War veterans.
Researchers from the Mount Sinai School of Medicine in New York and the James J. Peters VA Medical Center in the Bronx are evaluating veterans of the 1991 Gulf War with chronic multisymptom illness but without any exclusionary psychiatric or medical conditions. All subjects will be treated for a six-week time period with the mifepristone compound and then, a month later, treated with an alternative compound (placebo) in a crossover design. Researchers will then evaluate physical health, cognitive functioning and mental health in subjects and determine if there is improvement in these areas in relation to mifepristone administration.
"A positive outcome would provide a new therapeutic avenue for treating ill Gulf War veterans, for whom there are currently few treatment options," says Julia Golier, M.D., a psychiatrist at Mount Sinai. "The trial will also provide an important proof of concept of whether this type of drug will improve physical health and cognitive outcomes in symptomatic Gulf War veterans, thus improving their overall health."
The above post is reprinted from materials provided by US Department of Defense Congressionally Directed Medical Research Programs. Note: Content may be edited for style and length.
Cite This Page: